Literature DB >> 17525040

Oxycodone: a pharmacological and clinical review.

A Ordóñez Gallego1, M González Barón, E Espinosa Arranz.   

Abstract

Oxycodone is a semi-synthetic opioid with an agonist activity on mu, kappa and delta receptors. Equivalence with regard to morphine is 1:2. Its effect commences one hour after administration and lasts for 12 h in the controlled-release formulation. Plasma halflife is 3-5 h (half that of morphine) and stable plasma levels are reached within 24 h (2-7 days for morphine). Oral bioavailability ranges from 60 to 87%, and plasma protein binding is 45%. Most of the drug is metabolised in the liver, while the rest is excreted by the kidney along with its metabolites. The two main metabolites are oxymorphone--which is also a very potent analgesic--and noroxycodone, a weak analgesic. Oxycodone metabolism is more predictable than that of morphine, and therefore titration is easier. Oxycodone has the same mechanism of action as other opioids: binding to a receptor, inhibition of adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability. These mechanisms also play a part in the onset of dependence and tolerance. The clinical efficacy of oxycodone is similar to that of morphine, with a ratio of 1/1.5-2 for the treatment of cancer pain. Long-term administration may be associated with less toxicity in comparison with morphine. In the future, both opioids could be used simultaneously at low doses to reduce toxicity. It does not appear that there are any differences between immediate and slow-release oxycodone, except their half-life is 3-4 h, and 12 h, respectively. In Spain, controlled-release oxycodone (OxyContin) is marketed as 10-, 20-, 40- or 80-mg tablets for b.i.d. administration. Tablets must be taken whole and must not be broken, chewed or crushed. There is no food interference. The initial dose is 10 mg b.i.d. for new treatments and no dose reduction is needed in the elderly or in cases of moderate hepatic or renal failure. Immediate-release oxycodone (OxyNorm) is also available in capsules and oral solution. Side effects are those common to opioids: mainly nausea, constipation and drowsiness. Vomiting, pruritus and dizziness are less common. The intensity of these side effects tends to decrease over the course of time. Oxycodone causes somewhat less nausea, hallucinations and pruritus than morphine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525040     DOI: 10.1007/s12094-007-0057-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  45 in total

Review 1.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.

Authors:  D P Benziger; R F Kaiko; J B Miotto; R D Fitzmartin; R F Reder; M Chasin
Journal:  J Pharm Sci       Date:  1996-04       Impact factor: 3.534

3.  Oral oxycodone hydrochloride versus epidural anaesthesia for pain control after radical retropubic prostatectomy.

Authors:  Lena Hohwü; Olof Akre; Lennart Bergenwald; Magnus Törnblom; Ove Gustafsson
Journal:  Scand J Urol Nephrol       Date:  2006

4.  No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients.

Authors:  Julia Riley; Joy R Ross; Dag Rutter; Athol U Wells; Katherine Goller; Ron du Bois; Ken Welsh
Journal:  Support Care Cancer       Date:  2005-06-11       Impact factor: 3.603

5.  A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model.

Authors:  Camilla Staahl; Lona Louring Christrup; Søren Due Andersen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Pain       Date:  2006-04-04       Impact factor: 6.961

6.  Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.

Authors:  M E Hale; R Fleischmann; R Salzman; J Wild; T Iwan; R E Swanton; R F Kaiko; P G Lacouture
Journal:  Clin J Pain       Date:  1999-09       Impact factor: 3.442

7.  Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy.

Authors:  C Peter N Watson; Dwight Moulin; Judith Watt-Watson; Allan Gordon; John Eisenhoffer
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

8.  Psychomotor, respiratory and neuroendocrinological effects of a mu-opioid receptor agonist (oxycodone) in healthy volunteers.

Authors:  U Saarialho-Kere; M J Mattila; T Seppälä
Journal:  Pharmacol Toxicol       Date:  1989-10

9.  Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain.

Authors:  E Bruera; M Belzile; E Pituskin; R Fainsinger; A Darke; Z Harsanyi; N Babul; I Ford
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

10.  Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.

Authors:  C P Watson; N Babul
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  39 in total

1.  Health-Related Quality-of-Life Outcomes in Patients Treated with Push-Pull OROS Hydromorphone versus Extended-Release Oxycodone for Chronic Hip or Knee Osteoarthritis Pain: A Randomized, Open-Label, Parallel-Group, Multicenter Study.

Authors:  Kavita Gajria; Mark Kosinski; Jeff Schein; Shane Kavanagh; Dominique Dubois
Journal:  Patient       Date:  2008-07-01       Impact factor: 3.883

Review 2.  Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.

Authors:  Celeste B Burness; Gillian M Keating
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

3.  Opioids induce dissociable forms of long-term depression of excitatory inputs to the dorsal striatum.

Authors:  Brady K Atwood; David A Kupferschmidt; David M Lovinger
Journal:  Nat Neurosci       Date:  2014-02-23       Impact factor: 24.884

4.  Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: A meta-analysis of randomized controlled trials.

Authors:  Yu-Mei Wang; Zu-Wang Liu; Jia-Li Liu; Lei Zhang
Journal:  Exp Ther Med       Date:  2010-05-10       Impact factor: 2.447

Review 5.  Oxycodone combinations for pain relief.

Authors:  R B Raffa; J V Pergolizzi; D J Segarnick; R J Tallarida
Journal:  Drugs Today (Barc)       Date:  2010-06       Impact factor: 2.245

6.  Mild Cognitive Impairment and Decline in Resting State Functional Connectivity after Total Knee Arthroplasty with General Anesthesia.

Authors:  Cheshire Hardcastle; Hua Huang; Sam Crowley; Jared Tanner; Carlos Hernaiz; Mark Rice; Hari Parvataneni; Mingzhou Ding; Catherine C Price
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 7.  Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder.

Authors:  Maureen A Mealy; Sharon L Kozachik; Michael Levy
Journal:  Pain Manag Nurs       Date:  2019-05-15       Impact factor: 1.929

8.  Sex Differences in the Rat Hippocampal Opioid System After Oxycodone Conditioned Place Preference.

Authors:  James D Ryan; Yan Zhou; Natalina H Contoreggi; Farah K Bshesh; Jason D Gray; Joshua F Kogan; Konrad T Ben; Bruce S McEwen; Mary Jeanne Kreek; Teresa A Milner
Journal:  Neuroscience       Date:  2018-10-11       Impact factor: 3.590

9.  Oxycodone induced delirium and agitation in an elderly patient following total right knee arthroplasty.

Authors:  Joseph H Crane; Katie J Suda
Journal:  Int J Clin Pharm       Date:  2011-08-19

10.  Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?

Authors:  Bruce Charles; Janet Hardy; Helen Anderson; Angela Tapuni; Rani George; Ross Norris
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.